Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of ABT-652 in Subjects With Excessive Daytime Sleepiness
Status:
Completed
Trial end date:
2011-04-01
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to evaluate the safety and tolerability of the drug ABT-652
given once daily to people with excessive daytime sleepiness. Subjects will be randomized to
either ABT-652 or placebo in three sequential dosing groups for a 1-week treatment period.